EKF Diagnostics Holdings PLC represents a strong commitment to providing innovative diagnostic solutions and improving patient outcomes. With a focus on precision medicine, the company aims to enhance healthcare delivery through advanced technologies. EKF Diagnostics values integrity, quality, and collaboration in its operations, fostering partnerships with healthcare professionals and researchers. By incorporating cutting-edge technologies and expertise, EKF Diagnostics strives to deliver accurate and reliable diagnostic tools for various medical conditions. The company's corporate philosophy emphasizes patient-centered care, technological advancements, and a drive for continuous improvement. EKF Diagnostics Holdings PLC constantly works towards advancing healthcare and empowering healthcare providers with reliable diagnostic solutions.

EKF Diagnostics Holdings PLC is primarily present in various countries and regions. These include the United Kingdom, Germany, Belgium, the United States, and Russia. With a global presence, EKF Diagnostics Holdings PLC has established a strong foothold in the healthcare industry. Its wide distribution network and strategic partnerships enable the company to provide innovative diagnostic solutions to healthcare professionals worldwide. EKF Diagnostics Holdings PLC's commitment to delivering accurate and reliable results makes it a trusted provider in the medical diagnostics market.

EKF Diagnostics Holdings PLC has achieved several significant milestones. The company successfully expanded its product portfolio by acquiring Stanbio Laboratory in 2011, which enabled them to provide a comprehensive range of diagnostic tests. In 2012, EKF Diagnostics entered into a collaboration agreement with Oragenics Inc. to develop and commercialize oral cancer diagnostic tests. Furthermore, they received US FDA clearance for their Quo-Test HbA1c analyzer in 2016, enhancing their presence in the diabetes diagnostics market. In 2018, EKF Diagnostics acquired DiaSpect Medical AB, a leading point-of-care hematology company. These milestones highlight the company's commitment to growth, innovation, and providing cutting-edge diagnostic solutions.

EKF Diagnostics Holdings PLC, a leading medical device and diagnostic services company, has a rich history and compelling background. Founded in 1990, EKF Diagnostics initially focused on developing enzymatic assays. Over the years, the company has grown exponentially, expanding its product portfolio and global presence. EKF Diagnostics is renowned for its cutting-edge technologies, such as point-of-care testing and molecular diagnostics, catering to various medical fields including diabetes, hematology, and oncology. The company's commitment to research, innovation, and high-quality products has earned it a strong reputation in the healthcare industry. EKF Diagnostics continues to thrive as a trusted provider of advanced diagnostic solutions, contributing to improved patient care worldwide.

The main competitors of EKF Diagnostics Holdings PLC in the market include companies such as Abbott Laboratories, Siemens Healthineers AG, and F. Hoffmann-La Roche Ltd. These companies are also prominent players in the medical diagnostics industry, offering a wide range of diagnostic products, including point-of-care testing solutions, clinical chemistry analyzers, and molecular diagnostics. However, EKF Diagnostics Holdings PLC distinguishes itself with its specialized focus on developing and manufacturing innovative diagnostic products for hematological, diabetes, and autoimmune conditions.

EKF Diagnostics Holdings PLC primarily operates in the medical diagnostics industry. With its robust portfolio of innovative diagnostic products and technologies, the company specializes in developing and manufacturing point-of-care analyzers, biomarker detection assays, and molecular diagnostics products. EKF Diagnostics Holdings PLC serves various sectors within the medical industry, such as clinical chemistry, hematology, diabetes, and infectious diseases. Leveraging its expertise, EKF Diagnostics aims to enhance patient outcomes and provide healthcare professionals with reliable tools for efficient diagnosis and monitoring.

The business model of EKF Diagnostics Holdings PLC revolves around the development, production, and distribution of innovative diagnostic tools and products. EKF Diagnostics specializes in point-of-care testing devices, molecular diagnostics, and central laboratory clinical chemistry. The company focuses on delivering cost-effective solutions that enable healthcare professionals to make accurate and timely diagnoses. EKF Diagnostics works closely with healthcare providers and laboratories worldwide to provide advanced diagnostic solutions that enhance patient care. By continuously investing in research and development, EKF Diagnostics aims to stay at the forefront of the diagnostic industry, addressing various medical needs efficiently and effectively.

The EKF Diagnostics Holdings P/E ratio is 23.14.

The EKF Diagnostics Holdings P/S ratio is 2.26.

The AlleAktien quality score for EKF Diagnostics Holdings is 3/10.

The expected EKF Diagnostics Holdings revenue is 55.8 M GBP.

The expected EKF Diagnostics Holdings profit is 5.46 M GBP.

EKF Diagnostics Holdings PLC is a company specializing in the development, manufacturing, and marketing of diagnostic and screening equipment for clinical laboratories. They focus on areas such as diabetes, hemoglobinopathies, hematology, infectious diseases, and cancer. Their business strategy includes selling products worldwide, capitalizing on the growing markets for point-of-care testing and mobile diagnostic devices. They achieve this through innovative technologies and partnerships with reputable research institutions and trade partners. The company's products include glucose meters, HbA1c analyzers, hemoglobinopathy analyzers, blood cell analyzers, and infection disease testing equipment. They also offer a range of products for cancer diagnostics. EKF Diagnostics operates globally with subsidiaries in Europe, Asia, and North America. They cater to various types of laboratories and offer custom solutions.

EKF Diagnostics Holdings pays a dividend of 0.01 GBP distributed over payouts per year.

The dividend cannot currently be calculated for EKF Diagnostics Holdings or the company does not pay out a dividend.

The ISIN of EKF Diagnostics Holdings is GB0031509804.

The WKN of EKF Diagnostics Holdings is 622434.

The ticker of EKF Diagnostics Holdings is EKF.L.

Over the past 12 months, EKF Diagnostics Holdings paid a dividend of 0.01 GBP . This corresponds to a dividend yield of about 4.32 %. For the coming 12 months, EKF Diagnostics Holdings is expected to pay a dividend of 0.01 GBP.

The current dividend yield of EKF Diagnostics Holdings is 4.32 %.

EKF Diagnostics Holdings pays a quarterly dividend. This is distributed in the months of December, December, December, December.

EKF Diagnostics Holdings paid dividends every year for the past 7 years.

For the upcoming 12 months, dividends amounting to 0.01 GBP are expected. This corresponds to a dividend yield of 3.93 %.

EKF Diagnostics Holdings is assigned to the 'Health' sector.

To receive the latest dividend of EKF Diagnostics Holdings from 12/1/2023 amounting to 0.012 GBP, you needed to have the stock in your portfolio before the ex-date on 11/2/2023.

The last dividend was paid out on 12/1/2023.

In the year 2023, EKF Diagnostics Holdings distributed 0.012 GBP as dividends.

The dividends of EKF Diagnostics Holdings are distributed in GBP.